Drugs that contain Semaglutide
1. List of Ozempic drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(2 years from now) | |
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(1 year, 4 months ago) | |
| US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(1 year, 4 months ago) | |
| US6899699 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(1 year, 4 months ago) | |
| US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(26 days from now) | |
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(11 months from now) | |
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(2 years from now) | |
| US11446443 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(2 years from now) | |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(2 years from now) | |
| US11311679 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(2 years from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(2 years from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(3 years from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(3 years from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(3 years from now) | |
| US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(3 years from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(3 years from now) | |
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(3 years from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(4 years from now) | |
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(8 years from now) | |
| US10335462 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Jan 16, 2023 |
| New Dosing Schedule (D) | Mar 28, 2025 |
Market Authorisation Date: 05 December, 2017
Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; Ozempic is indicated as an adjunct to diet and exercise to imp...
Dosage: SOLUTION;SUBCUTANEOUS
OZEMPIC family patents
58
United States
31
European Union
22
Denmark
16
Japan
15
China
14
Spain
11
Australia
11
Poland
10
Russia
9
Canada
8
Brazil
7
Austria
7
Portugal
7
Germany
5
Hungary
4
Mexico
3
Korea, Republic of
3
Slovenia
2
Norway
2
South Africa
2
Taiwan
1
Israel
1
Croatia
1
Netherlands
1
Cyprus
1
Hong Kong
1
RS
1
Turkey
2. List of Rybelsus drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(2 years from now) | |
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11382957 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(8 years from now) | |
| US9278123 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(8 years from now) | |
| US10960052 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid |
Dec, 2031
(8 years from now) | |
| US10086047 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(8 years from now) | |
| US10933120 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(9 years from now) | |
| US10278923 | NOVO | Oral dosing of GLP-1 compounds |
May, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Jan 16, 2023 |
Market Authorisation Date: 20 September, 2019
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET;ORAL
RYBELSUS family patents
21
United States
18
European Union
8
Japan
7
Korea, Republic of
7
China
6
Denmark
6
Spain
6
Portugal
6
Poland
6
Mexico
6
Hungary
5
Australia
5
Brazil
4
Croatia
4
Canada
4
Russia
4
Slovenia
4
South Africa
4
RS
3
Israel
3
Cyprus
3
Lithuania
2
Malaysia
2
Norway
2
Taiwan
1
Netherlands
1
Saudi Arabia
1
Austria
1
Ukraine
1
Germany
3. List of Wegovy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(2 years from now) | |
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9764003 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(10 years from now) | |
| US10888605 | NOVO | GLP-1 compositions and uses thereof |
Aug, 2038
(15 years from now) | |
| US11318191 | NOVO | GLP-1 compositions and uses thereof |
Feb, 2041
(17 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Jun 4, 2024 |
| New Patient Population (NPP) | Dec 23, 2025 |
Market Authorisation Date: 04 June, 2021
Treatment: Method for weight management according to a dose escalation schedule; Method for weight management
Dosage: SOLUTION;SUBCUTANEOUS
WEGOVY family patents
23
European Union
12
United States
7
Australia
7
Japan
6
Brazil
6
China
6
Taiwan
5
Canada
4
Israel
4
Korea, Republic of
4
Russia
4
Mexico
3
Colombia
3
Denmark
3
Spain
3
Portugal
3
Argentina
3
Hungary
2
Chile
2
Poland
2
Norway
1
Croatia
1
Netherlands
1
Peru
1
Austria
1
Singapore
1
Philippines
1
Morocco
1
Germany
1
Slovenia
1
South Africa
1
RS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic